GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » 1-Year ROIIC %

MiNK Therapeutics (MiNK Therapeutics) 1-Year ROIIC % : -2,593.01% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. MiNK Therapeutics's 1-Year ROIIC % for the quarter that ended in Mar. 2024 was -2,593.01%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for MiNK Therapeutics's 1-Year ROIIC % or its related term are showing as below:

INKT's 1-Year ROIIC % is ranked worse than
96.09% of 1458 companies
in the Biotechnology industry
Industry Median: -4.19 vs INKT: -2593.01

MiNK Therapeutics 1-Year ROIIC % Historical Data

The historical data trend for MiNK Therapeutics's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics 1-Year ROIIC % Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
- 216.03 -11,373.97 96.60 -2,866.79

MiNK Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -103.49 1,763.33 3,743.36 -2,866.79 -2,593.01

Competitive Comparison of MiNK Therapeutics's 1-Year ROIIC %

For the Biotechnology subindustry, MiNK Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's 1-Year ROIIC % falls into.



MiNK Therapeutics 1-Year ROIIC % Calculation

MiNK Therapeutics's 1-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -20.897 (Mar. 2024) - -29.428 (Mar. 2023) )/( 3.233 (Mar. 2024) - 3.562 (Mar. 2023) )
=8.531/-0.329
=-2,593.01%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


MiNK Therapeutics  (NAS:INKT) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


MiNK Therapeutics 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


MiNK Therapeutics (MiNK Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010